论文部分内容阅读
目的:本研究旨在分析总结癌-睾丸抗原TFDP3在乳腺癌中的表达规律,探究TFDP3表达与乳腺癌分型及发病进程关系。方法:通过对不同分型及分期的乳腺癌组织切片进行免疫组化检测,分析TFDP3在其中的表达情况,并结合样本来源患者的临床信息,对TFDP3的表达与乳腺癌分子分型、分期及预后的相关性进行统计分析。同时,通过Western Blot检测了5种乳腺癌细胞系(MDA-MB-231、MCF-7、SK-BR-3、T47D及MCF-10A)中TFDP3的表达情况,并通过细胞免疫荧光实验,检测TFDP3在细胞中的定位。结果:TFDP3在已检测的乳腺癌样本中的表达率为49%。乳腺癌临床分子分型标记物HER2的表达与TFDP3的表达呈正相关,但乳腺癌的分期、临床病理分型以及临床分子分型标记物ER、PR的表达均与肿瘤组织中TFDP3的表达无相关性。结论:TFDP3在各在乳腺癌组织中高表达,其表达量与HER2的表达量呈正性相关。这为研究已TFDP3为靶点的乳腺癌免疫治疗,提供了新的依据。
OBJECTIVE: This study aims to analyze the expression of cancer-testis antigen TFDP3 in breast cancer and to explore the relationship between TFDP3 expression and breast cancer classification and pathogenesis. Methods: The expression of TFDP3 was analyzed by immunohistochemistry in different sections and stages of breast cancer. The expression of TFDP3 was correlated with the molecular classification of breast cancer, Prognosis correlation statistical analysis. At the same time, the expression of TFDP3 in 5 breast cancer cell lines (MDA-MB-231, MCF-7, SK-BR-3, T47D and MCF-10A) was detected by Western Blot and detected by cell immunofluorescence The localization of TFDP3 in cells. Results: The expression of TFDP3 in tested breast cancer samples was 49%. The expression of HER2 in breast cancer was positively correlated with the expression of TFDP3, but there was no correlation between the expression of TFDP3 and the staging, clinicopathological type and ER, PR in breast cancer Sex. Conclusion: TFDP3 is overexpressed in breast cancer tissues, and its expression is positively correlated with the expression of HER2. This provides a new basis for the study of breast cancer immunotherapy with TFDP3 as a target.